

CANCER GENOMICS & PROTEOMICS

Published by the International Institute of Anticancer Research
ISSN: 1109-6535

Volume 3, 2006

Editorial Board

- A. Seth** Editor-in-Chief
Laboratory of Molecular Pathology, Sunnybrook and Women's CHSC,
Toronto, ON, Canada
- J.G. Delinassios** Managing Editor and Executive Publisher,
International Institute of Anticancer Research, Athens, Greece
- L.A. Aaltonen** Department of Medical Genetics, University of Helsinki, Finland
S. Aaronson Derarld H. Ruttenberg Cancer Center, Mount Sinai School of Medicine, New York, NY, USA
J.D. Aitchison Institute for Systems Biology, Seattle, WA, USA
W. Ansorge IAET, Borex, Switzerland
S. Antonarakis Division of Medical Genetics, University of Geneva Medical School, Switzerland
F.G. Barr Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA
A.M. Chinnaiyan Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA
B.F.C. Clark Department of Molecular Biology, University of Aarhus, Denmark
R. Clarke Vincent T. Lombardi Cancer Center, Georgetown University School of Medicine, Washington, DC, USA
I. Dunham The Wellcome Trust Sanger Centre, Wellcome Trust Genome Campus, Cambridge, UK
N.A. Ellis Department of Human Genetics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
J.A. Fernandes-Pol Metalloproteomics, LLC, Chesterfield, MO, USA
C.V. Forst McClintock Resource, Bioscience Division, Los Alamos National Laboratory, NM, USA
M. Fountoulakis F. Hoffman - La Roche Pharmaceutical Research, Basel, Switzerland
W.L. Gerald Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
J.W. Gray Cancer Genetics Program, Comprehensive Cancer Center, University of California San Francisco, CA, USA
B.B. Haab Van Andel Research Institute, Grand Rapids, MI, USA
J.D. Hoheisel Deutsches Krebsforschungszentrum, Genome Research and Bioinformatics, Heidelberg, Germany
R.P. Huang Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA, USA
T.H.M. Huang Comprehensive Cancer Center, Human Cancer Genetics Program, Ohio State University, Columbus, OH, USA
- Yasumasa Ito** Orthopedic Division, National Cancer Center Hospital, Tokyo, Japan
Yoshiaki Ito Institute of Molecular and Cell Biology, Clinical Research Centre, Singapore
V.C. Jordan Diana, Princess of Wales Cancer Research Department, Lynn Sage Breast Cancer Research Program, Northwestern University Medical School, Chicago, IL, USA
- A. Kallioniemi** Laboratory of Cancer Genetics, Institute of Medical Technology, Tampere University Hospital, Finland
O.P. Kallioniemi Medical Biotechnology Group, VTT Technical Research Centre of Finland, Turku, Finland
M. Kanehisa Bioinformatics Center, Institute for Chemical Research, Kyoto University, Japan
S.E. Kern Department of Oncology, The Johns Hopkins School of Medicine, Baltimore, MD, USA
K. Khalili College of Science and Technology, Center for Neurovirology and Cancer Biology, Temple University, Philadelphia, PA, USA
- S.D. Kottaridis** Department of Virology, Hellenic Anticancer Institute, Athens, Greece
P. Lichter Deutsches Krebsforschungszentrum, Heidelberg, Germany
G. Lubec Department of Pediatrics, University of Vienna, Austria
P.J. McCormick Center for Comp. Functional Genomics, VA Medical Center University at Albany, SUNY, Rensselaer, NY, USA
- J.D. Minna** Hamon Center for Therapeutic Oncology, University of Texas, Southwestern Medical Center at Dallas, TX, USA
- F. Mitelman** Department of Clinical Genetics, University Hospital, Lund, Sweden
P. Nelson Fred Hutchinson Cancer Research Center, Seattle, WA, USA

R. Ohlsson	Department of Development and Genetics, Evolution Biology Center, Uppsala University, Sweden
I. Pastan	Laboratory of Molecular Biology, NCI, NIH, Bethesda, MD, USA
J. Quackenbush	The Institute of Genomic Research, Rockville, MD, USA
G. Rechavi	Pediatric Hemato-Oncology Department, Sheba Medical Center, Tel-Hashomer, Israel
R.H. Reeves	Department of Physiology, Johns Hopkins University, School of Medicine, Baltimore, MD, USA
K.L. Reichelt	Institute of Pediatric Research, The National Hospital, University of Oslo, Norway
T. Ried	Center for Cancer Research, Genetics Branch, NCI, NIH, Bethesda, MD, USA
K.D. Rodland	Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA
C. Sansom	The School of Crystallography, Birbeck College, University of London, UK
Y. Sakaki	Human Genome Research Group, RIKEN Genomic Sciences Center, Yokohama, Japan
N.A. Saunders	Centre for Immunology and Cancer Research, Princess Alexandra Hospital, University of Queensland, Australia
S.W. Scherer	The Hospital for Sick Children, Department of Genetics, University of Toronto, ON, Canada
G.V. Sherbet	University of Newcastle, Merz Court, Department of Electrical and Electronic Engineering, Newcastle-upon-Tyne, UK
Y. Shimonishi	Nagahama Institute of Bioscience and Technology, Shiga, Japan
S. Smith	City of Hope Cancer Center, Department of Cell and Tumor Biology, Duarte, CA, USA
D. Sudar	Life Sciences Division, Lawrence Berkeley Laboratory, Berkeley, CA, USA
A.-C. Syvänen	Department of Medical Sciences, Uppsala University Hospital, Sweden
K. Tanaka	Department of Orthopaedic Surgery, Kyushu University, Fukuoka, Japan
J.M. Trent	Tgen, Phoenix, AZ, USA
G. Tsangaris	Foundation of Biomedical Research of the Academy of Athens, Central Unit of Genomics- Proteomics, Athens, Greece
L.-C. Tsui	The Hospital for Sick Children, University of Toronto, ON, Canada
A. Ullrich	Department of Molecular Biology, Max-Planck Institute of Biochemistry, Martinsried, Germany
G.F. Vande Woude	Laboratory of Molecular Oncology, Van Andel Institute, Grand Rapids, MI, USA
D.K. Watson	Department of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA
K. Williams	Keck Laboratory, Department of Molecular Biophysics and Biochemistry, New Haven, CT, USA

Articles in CANCER GENOMICS & PROTEOMICS are regularly indexed in the following bibliographic services: CAS (Chemical Abstracts Service); BIOLOGICAL ABSTRACTS; EMBASE and BIOBASE, Compendex, GEOBASE, EMBiology, FLUIDEX, Scopus (Elsevier Bibliographic Databases); BIOSIS PREVIEWS; LEEDS MEDICAL INFORMATION; CSA ILLUMINA (Cambridge Scientific Abstracts, including: Oncogenes & Growth Factors, Genetics, Medical & Pharmaceutical Biotechnology, Bioengineering); All-Russian Institute of Scientific and Technical Information – VINITI Abstracts Journal; PubsHub.

Editorial Office:

International Institute of Anticancer Research
 1st km Kapandritiou-Kalamou Road,
 P.O. Box 22, Kapandriti, Attiki, 19014, Greece.
 Tel: 0030 22950 52945, Fax: 0030 22950 53389
 e-mail: journals@iiar-anticancer.org. Website: www.iiar-anticancer.org

Manuscripts, correspondence, requests for sample copies and orders should be addressed to: Dr John G. Delinassios, Managing Editor, Editorial Office, Cancer Genomics & Proteomics, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, Kapandriti, Attiki, 19014, Greece. Tel.: 0030 22950 52945, Fax: 0030 22950 53389, e-mail (Editorial Office): journals@iiar-anticancer.org. e-mail (Managing Editor): editor@iiar-anticancer.org

Manuscripts from North America may be sent to the Editor-in-Chief, Prof. A. Seth, CGP, Laboratory of Molecular Pathology, Sunnybrook and Women's College Health Sciences Center, 2075 Bayview Avenue, Room E-423, Toronto, ON. Canada M4N 3M5. Fax: 416 978 5956, e-mail: genomics.proteomics@utoronto.ca

Acknowledgements

The following Organisations supported many of the works published in CANCER GENOMICS & PROTEOMICS, Volume 3, 2006.

Academy of Finland
 Association de la Recherche contre le Cancer, France
 Association Nationale de la Recherche Technique, France
 Associazione Italiana per la Ricerca sul Cancro (AIRC), Italy
 Canary Fund, U.S.A.
 Cancéropôle Grand Ouest, France
 Changhua Christian Hospital, Taiwan, R.O.C.
 China Medical University Hospital, Taichung City, Taiwan, R.O.C.
 Chulabhorn Research Institute, Thailand
 Comité du Puy-de-Dôme, France
 Concern Foundation, U.S.A.
 Curie-CEA, France
 DOD Breast Cancer Research Programs, U.S.A.
 Electricité de France (EDF)
 European Commission Grant "Spiderman"
 European Union (European Regional Development Fund)
 Finnish Cancer Society
 Finska Läkaresällskapet, Finland
 Gene and Mary Ann Walters Pancreatic Cancer Foundation, U.S.A.
 General Secretariat for Research and Technology, Greece
 Generalitat Valenciana, Spain
 Greek Ministry of Education
 Helsinki University Hospital Research Funds, Finland
 Hong Kong Research Grants Council, China
 Ireland's Higher Educational Authority Program for Research
 Italian Ministry of Health
 Italian Neuroblastoma Foundation
 Japan Private School Foundation
 Johansson K. Albin Foundation, Finland
 K. Albin Johansson Foundation, Finland
 Kuwait University Research Administration Grant
 La Ligue Nationale Française de Lutte Contre le Cancer, France
 Ligue Régionale contre le Cancer de Loire Atlantique, France
 Lyon's Club-La Baule / Pays Guérandais, France
 Ministère des Finances et de l' Industrie, France
 Ministero dell' Università e della Ricerca Scientifica e Tecnologica, Italy
 Ministry of Education, Culture, Sports, Science and Technology, Japan
 Ministry of Health, Labor and Welfare, Japan
 Mitchell Cancer Institute, Mobile, AL, U.S.A.
 Nantes Pays de Loire, France
 National Cancer Institute, U.S.A.
 National Institutes of Health, U.S.A.
 National Science Council, Taiwan
 New Energy and Industrial Technology Development Organization (NEDO), Japan
 Pfizer, France
 RISC-RAD European Contract, France
 Robert J. Kleberg Jr. and Helen C. Kleberg Foundation, U.S.A.
 Sigrid Jusélius Foundation, Finland
 Smoking Research Foundation, Japan
 T.J. Martell Foundation, U.S.A.
 University of Crete, Greece
 Vanderbilt-Ingram Comprehensive Cancer Center, Nashville, TN, U.S.A.
 Vehicle Racing Commemorative Foundation, Japan
 Woodruff Health Science Fund, U.S.A.

Contents, Volume 3, 2006

Number 1

* Gene Expression and Proteomic Analysis of Pancreatic Cancer: a Recent Update. R. CHEN, S. PAN, D.A. CRISPIN, T.A. BRETNALL (<i>Seattle, WA, USA</i>).....	1
* Proteomics and Bioinformatics in Biomedical Research. T. KISLINGER, I. JURISICA (<i>Toronto, ON, Canada</i>).....	11
Cytoplasmic Localization of Cyclin Kinase Inhibitor p21 Delays the Progression of Apoptosis. D. ARAI, N. NOMURA, K. FUKUCHI, K. GOMI (<i>Tokyo, Japan</i>).....	29
Loss of Chromosome 13q is Associated with Malignant Potential in Pulmonary Carcinoids. K. INAMURA, R. FURUTA, Y. SATOH, T. SHIRAKAWA, S. OKUMURA, K. NAKAGAWA, M.I FUJIWARA, E. TSUCHIYA, Y. ISHIKAWA (<i>Tokyo; Yokohama, Japan</i>)	39
Rapid and Sensitive Assay of <i>K-ras</i> Mutations in Pancreatic Cancer by Electrochemical Detection with Ferrocenyl-naphthalene-diimide. N. ISHIKAWA, T. MIYA, K. MIZUMOTO, K. OHUCHIDA, E. NAGAI, K. YAMAGUCHI, M. AMANO, S. TAKENAKA, M. TANAKA (<i>Fukuoka; Chiba, Japan</i>)	47
Down-regulation of Cdc25c, CDK1 and Cyclin B1 and Up-regulation of Wee1 by Curcumin Promotes Human Colon Cancer Colo 205 Cell Entry into G2/M-phase of Cell Cycle. C-C. SU, J-G. LIN, G-W.I CHEN, W-C. LIN, J-G. CHUNG (<i>Taichung, Taiwan, ROC</i>).....	55
Improving Gene Expression Sample Classification Using Support Vector Machine Ensembles Aggregated by Boosting. A. DRAGOMIR, A. BEZERIANOS (<i>Patras, Greece</i>)	63
Reviews (pages 1, 11)	

Number 2

Early Growth Response-1 Suppresses Human Fibrosarcoma Cell Invasion and Angiogenesis. R. HUANG, S. LI, W. YANG, L. CHEN, C. YAO, R-P. HUANG (<i>Atlanta, GA, USA; Guangzhou, China</i>)	71
Transient Expression of a Major Ampullate Spidroin 1 Gene Fragment from <i>Euprosthenoops</i> sp. in Mammalian Cells. S. GRIP, A. RISING, H. NIMMERVOLL, E. STORCKENFELDT, S.J. MCQUEEN-MASON, N. POUCHKINA-STANTCHEVA, F. VOLLRATH, W. ENGSTRÖM, A. FERNANDEZ-ARIAS (<i>Uppsala, Sweden; York; Oxford, UK</i>)	83
Gene Expression Profiles Discriminate between Pathological Complete Response and Resistance to Neoadjuvant FEC100 in Breast Cancer. M. MILLOUR, C. CHARBONNEL, F. MAGRANGEAS, S. MINVIELLE, L. CAMPION, W. GOURAUD, M. CAMPONE, R. DÉPORTE-FÉTY, Y-J. BIGNON, F. PENAULT-LLORCA, P. JÉZÉQUEL (<i>Nantes - Saint Herblain; Clermont-Ferrand; Nantes, France</i>)	89
Microarray Expression Profiling of ABC Transporters in Human Breast Cancer. J-P. GILLET, J. SCHNEIDER, V. BERTHOLET, F. DE LONGUEVILLE, J. REMACLE, T. EFFERTH (<i>Namur, Belgium; Madrid, Spain; Heidelberg, Germany</i>)	97

Alteration of Apoptotic Regulatory Molecules in Conventional Renal Cell Carcinoma Influenced by Chronic Long-term Low-dose Ionizing Radiation Exposure in Humans Revealed by Tissue Microarray. A. ROMANENKO, L. MORELL-QUADRENY, D. RAMOS, A. VOZIANOV, A. LLOMBART-BOSCH (Kiev, Ukraine; Valencia, Spain).....	107
Gene Expression in Human Acute Cutaneous and Hepatic Graft-Versus-Host Disease after Allogeneic Bone Marrow Transplantation. B. CHOUFI, N. CHALABI, L. LE CORRE, L. DELORT, S. SATHI, Y-J. BIGNON, D. BERNARD-GALLON (Clermont-Ferrand, France).....	113
Proteomic Analysis of Liver from Transgenic Mice Overexpressing Small Heterodimer Partner. K. KOUYIANOU, S. GARBIS, K. BOULIAS, P. DIMITRAKI, M. FOUNTOULAKIS, G. TSIOTIS (Athens; Heraklion, Greece).....	119
Number 3-4	
* RNA Interference with siRNA. H. JOYCE, I. BRAY, M. CLYNES (Dublin, Ireland).....	127
* Genomic Instability and Breast Cancer Progression. S. INGVARSSON (Reykjavik, Iceland).....	137
* Design of Nanoparticles as Drug Carriers for Cancer Therapy. J. ZHANG, C.Q. LAN, M. POST, B. SIMARD, Y. DESLANDES, T.H. HSIEH (Ottawa, ON, Canada).....	147
* Molecular Replacement for Cancer Metabolic and Mitochondrial Dysfunction, Fatigue and the Adverse Effects of Cancer Therapy. G.L. NICOLSON, K.A. CONKLIN (Huntington Beach; Los Angeles, CA, USA).....	159
Gene Expression Profiles of CD133-positive Fractions Predict the Survival of Individuals with Acute Myeloid Leukemia. Y. YAMASHITA, J. OHASHI, Y. HIRAI, Y.L. CHOI, R. KANEDA, S.-I. FUJIWARA, Y. ARAI, M. AKUTSU, C. TSUTSUMI, Y. MIYAZAKI, K. USUKI, M. TERAMURA, K. MITANI, Y. KANO, M.C. O'NEILL, A. URABE, M. TOMONAGA, K. OZAWA, H. MANO (Tochigi; Tokyo; Nagasaki; Saitama, Japan; Baltimore, MD, USA).....	169
Effect of Vitamin E on Cytochrome P450 mRNA Levels in Cultured Hepatocytes (HepG2) and in Rat Liver. C. HUNDHAUSEN, J. FRANK, G. RIMBACH, E. STOECKLIN, P.Y. MULLER, L. BARELLA (Kiel, Germany; Basel, Switzerland).....	183
Association of HLA-DRB1 and -DQB1 with Classic Kaposi's Sarcoma in Mainland Italy. F.R. GUERINI, C. AGLIARDI, R. MANCUSO, L. BRAMBILLA, R. BIFFI, S. FERRUCCI, L. ZANETTA, M. ZANZOTTERA, M. BRAMBATI, V. BONESCHI, P. FERRANTE (Milan, Italy).....	191
* Gene Expression Microarray Technology: Some Applications in Lung Cancer Research. L. BREEN, L. O' DRISCOLL, M. CLYNES (Dublin, Ireland).....	197
* Metastasis Promoter S100A4 is a Potential Molecular Therapeutic Target. G.V. SHERBET (Newcastle upon Tyne, UK; Huntington Beach, CA, USA).....	203
* Laser Microdissection: Application to Carcinogenesis. F.E. AHMED (Greenville, NC, USA).....	217
* Considerations Regarding the Use of Blood Samples in the Proteomic Identification of Biomarkers for Cancer Diagnosis. C.V. SAPAN, R.L. LUNDBLAD (Chapel Hill, NC, USA).....	227
Methylation Inactivates Expression of CDP-diacylglycerol Synthase 1 (CDS1) in Hepatocellular Carcinoma. K.-T. YEH, K.-P. TANG, Y.-L. CHEN, W.-W. SU, Y.-F. WANG, J.-G. CHANG (Taichung; Changhua; Taipei; Taiwan, ROC).....	231

Reduced Expression of the Cell Cycle Regulator p27 ^{Kip1} within the Invasion Front of Renal Cell Carcinomas Proved to be a Significant Marker for Disease-specific Survival. A.S. MERSEBURGER, E. VON DER HEYDE, A. KOBIERSKI, U. WEGENER, M. MENGEL, U. JONAS, J. SERTH, M. KUCZYK (<i>Tübingen; Hannover, Germany</i>)	239
Oligonucleotide Array Comparative Genomic Hybridization Profiling of Neuroblastoma Tumours. P. SCARUFFI, S. MORETTI, S. COCO, K. MAZZOCCO, R. DEFFERRARI, D. ALBINO, S. BONASSI, G.P. TONINI (<i>Genoa, Italy</i>)	245
* Proteomics in Cancer Research and Diagnosis; An Update. V. IFANDI, S.E. SLADE, M. KHAN (<i>Coventry, UK</i>)	253
Relationship among Genetic Alterations, DNA Content, and Clinicopathological Features in Primary Lung Adenocarcinomas. K. UEDA, Y. KANEDA, M. HAYASHI, M. JINBO, T.-S. LI, K. HAMANO (<i>Yamaguchi, Japan</i>)	265
Correlative Analysis of DNA Methyltransferase Expression and Promoter Hypermethylation of Tumor Suppressor Genes in Hepatocellular Carcinoma. T.-W. LAM, J.H.-M. TONG, K.-F. TO, A. CHAN, C.-T. LIEW, P.B.-S. LAI, N. WONG (<i>Shatin, SAR Hong Kong, China</i>)	271
Reviews (pages 127, 137, 147, 159, 197, 203, 217, 227, 253)	

Number 5

Molecular Assessment of the Tumor Protein Microenvironment Using Imaging Mass Spectrometry. R.L. CALDWELL, A. GONZALEZ, S.R. OPPENHEIMER, H.S. SCHWARTZ, R.M. CAPRIOLI (<i>Nashville, TN, USA</i>).....	279
cDNA Microarray Analysis of Gene Expression in Ovarian Cancer Cells After Treatment with Carboplatin and Paclitaxel. L. RANDALL-WHITIS, D.D. TAYLOR, Ç. GERÇEL-TAYLOR (<i>Louisville, KY, USA</i>).....	289
Deregulated Pathways in a Human Lymphoblastoid Cell Line after Low Doses of Gamma Irradiation. S. CHEVILLARD, N. UGOLIN, O. RIGAUD, K. ORY, C. LEVALOIS, R. MAXIMILIEN, B. MALFOY (<i>Fontenay-aux-Roses cedex; Paris, France</i>).....	295
* Basics of Diagnostic DNA Microarray Technology. Case Study: Hepatocellular Carcinoma. A. EL-ANEED, J. BANOUB (<i>St. John's, NL, Canada</i>)	311
Non-coding MicroRNAs <i>hsa-let-7g</i> and <i>hsa-miR-181b</i> are Associated with Chemoresponse to S-1 in Colon Cancer. G. NAKAJIMA, K. HAYASHI, Y. XI, K. KUDO, K. UCHIDA, K. TAKASAKI, M. YAMAMOTO, J. JU (<i>Mobile, AL, USA; Tokyo, Japan</i>).....	317
The Proteome Profile of the Human Osteosarcoma Saos2 Cell Line. K.N. NIFOROU, A.K. ANAGNOSTOPOULOS, K. VOUGAS, C. KITTAS, V.G. GORGOLIS, G.T. TSANGARIS (<i>Athens, Greece</i>)	325
Review (page 311)	

Number 6

New Insights into the Cellular Pathways Affected in Primary Uterine Leiomyosarcoma. S. KAUR, MARCELO L. LARRAMENDY, M. GENTILE, C. SVARVAR, R. KOIVISTO-KORANDER, H. VAUHKONEN, I. SCHEININ, A. LEMINEN, R. BÜTZOW, T. BÖHLING, S. KNUUTILA (<i>Helsinki, Finland; La Plata, Argentina</i>).....	347
--	-----

Proteomic Analysis of the MCF7 Breast Cancer Cell Line. J. HARDOUIN, L. CANELLE, C. VLIEGHE, J-P. LASSERRE, M. CARON, R. JOUBERT-CARON (<i>Bobigny Cedex, France</i>).....	355
A Comparison of KGF Receptor Expression in Various Types of Human Cancer. X-P. ZANG, MEGAN R. LERNER, STEVEN J. BAHR, D.J. BRACKETT, J.T PENTO (<i>Oklahoma, OK, USA</i>)	369
Expression Analysis for the Identification of Genes Involved in Acquired Resistance to Cisplatin in Osteosarcoma Cells. K. TAKAZAWA, H. TSUCHIYA, U. YOSHIMICHI, Y. KANAZAWA, S. II, K. TOMITA (<i>Kanazawa; Ishikawa, Japan</i>).....	373
Resveratrol Regulation of PI3K-AKT Signaling Pathway Genes in MDA-MB-231 Breast Cancer Cells. O.A RACHID, M. ALKHALAF (<i>Safat, Kuwait</i>)	383
Proteomic Studies of Galectin-3 Expression in Human Thyroid Diseases by Immunodetection. P. SUBHASITANONT, C. SRISOMSAP, P. PUNYARIT, J. SVASTI (<i>Bangkok, Thailand</i>).....	389
Volume 3, 2006, Index.....	395

Subject Index

(Figures refer to page numbers)

- ABC transporter, cluster analysis, microarray, multidrug resistance, 97
- Acute myeloid leukemia, CD133, gene expression profile, prognosis, DNA microarray, 169
- Angiogenesis, cancer invasion, cell cycle regulation, cytoskeletal dynamics, growth factor signalling, lymphangiogenesis, metastasis, S100A4, therapeutic target, VEGF signalling, review, 203
- Angiogenesis, Egr-1, fibrosarcoma, invasion, metastasis, protein arrays, TIMP-2, 71
- Antioxidants, oxidative stress, mitochondria, coenzyme Q10, lipid peroxidation, electron transport chain, chemotherapy, lipid replacement, 159
- Apoptosis, cyclin kinase inhibitor p21, DNA damage, γ -irradiation, site-directed mutant, 29
- Array CGH, DNA copy number changes, uterine leiomyosarcoma, pathway analysis, 347
- Assymmetric PCR (A-PCR), electrochemical array (ECA) chip, ferrocenyl-naphthalene-diimide (FND), *k-ras* mutation, restriction enzyme BstNI, 47
- BAX, conventional renal cell carcinoma, ionizing radiation, Chernobyl accident, Bcl-2, Bcl-x, TRAIL-R2 (DR5), NF- κ B (p65, p50), 107
- Bcl-2, conventional renal cell carcinoma, ionizing radiation, Chernobyl accident, Bcl-x, BAX, TRAIL-R2 (DR5), NF- κ B (p65, p50), 107
- Bcl-x, conventional renal cell carcinoma, ionizing radiation, Chernobyl accident, Bcl-2, BAX, TRAIL-R2 (DR5), NF- κ B (p65, p50), 107
- Bioinformatics, proteomics, mass spectrometry, cancer biology, heart disease, diabetes, review, 11
- Biomarkers, proteomics, blood plasma, serum, review, 227
- Biomarkers, proteomics, cancer diagnosis, review, 253
- Blood plasma, proteomics, biomarkers, serum, review, 227
- Boosting, gene expression, classification, support vector machines, ensemble learning, feature selection, 63
- Breast cancer, genomic instability, chromosomal abnormalities, cancer progression, review, 137
- Breast cancer, MCF7 cell line, proteome, mass spectrometry, 2-DE databases, 355
- Breast cancer, neoadjuvant fluorouracil, epirubicin and cyclophosphamide chemotherapy, gene expression profiles, drug resistance, 89
- Cancer biology, proteomics, mass spectrometry, bioinformatics, heart disease, diabetes, review, 11
- Cancer chemotherapy, drug delivery, nanoparticles, polymer- and liposome-systems, magnetic nanohybrids, review, 147
- Cancer diagnosis, proteomics, biomarkers, review, 253
- Cancer invasion, angiogenesis, cell cycle regulation, cytoskeletal dynamics, growth factor signalling, lymphangiogenesis, metastasis, S100A4, therapeutic target, VEGF signalling, review, 203
- Cancer prevention, resveratrol, PI3K pathway, c-fos, p70S6K, predictive cancer markers, microarray, 383
- Cancer progression, genomic instability, breast cancer, chromosomal abnormalities, review, 137
- Cancer, KGFR, cDNA cancer array, gene expression, progression, 369
- Cancer, RNA interference, siRNA, microRNA, review, 127
- Carcinoid, lung, chromosome 13q, comparative genomic hybridization, retinoblastoma protein, 39
- CD133, acute myeloid leukemia, DNA microarray, 169
- Cdc25c, curcumin, cell cycle arrest, cyclin B1, CDK1, Wee1, 55
- CDK1, curcumin, cell cycle arrest, Cdc25c, cyclin B1, Wee1, 55
- cDNA cancer array, KGFR, cancer, gene expression, progression, 369
- CDP-diacylglycerol synthase 1, hepatocellular carcinoma, methylation, mutation analysis, 231
- Cell cycle arrest, curcumin, Cdc25c, cyclin B1, CDK1, Wee1, 55
- Cell cycle regulation, angiogenesis, cancer invasion, cytoskeletal dynamics, growth factor signalling, lymphangiogenesis, metastasis, S100A4, therapeutic target, VEGF signalling, review, 203
- Ceramide, transcriptome, gamma radiation, low doses, stress kinases, 295
- c-fos, resveratrol, PI3K pathway, p70S6K, cancer prevention, predictive cancer markers, microarray, 383
- CGH, neuroblastoma, microarray, MYCN, chromosome 1p, 245
- Chemotherapy, ovarian cancer, resistance, DNA damage, 289
- Chemotherapy, oxidative stress, mitochondria, coenzyme Q10, lipid peroxidation, electron transport chain, antioxidants, lipid replacement, 159
- Chernobyl accident, conventional renal cell carcinoma, ionizing radiation, Bcl-2, Bcl-x, BAX, TRAIL-R2 (DR5), NF- κ B (p65, p50), 107
- Chromosomal abnormalities, genomic instability, breast cancer, cancer progression, review, 137
- Chromosome 13q, lung, carcinoid, comparative genomic hybridization, retinoblastoma protein, 39
- Chromosome 1p, neuroblastoma, microarray, CGH, MYCN, 245
- Cisplatin, osteosarcoma, drug-resistance, DNA microarray, 373
- Classic Kaposi's sarcoma, human leukocyte antigens, human herpesvirus 8, 191
- Classification, gene expression, support vector machines, boosting, ensemble learning, feature selection, 63
- Cluster analysis, ABC transporter, microarray, multidrug resistance, 97
- Coenzyme Q10, oxidative stress, mitochondria, lipid peroxidation, electron transport chain, chemotherapy, antioxidants, lipid replacement, 159
- Colon cancer, miRNA, S-1, 317
- Comparative genomic hybridization, lung adenocarcinoma, laser scanning cytometry, DNA ploidy, prognosis, lymph node metastasis, 265

- Comparative genomic hybridization, lung, carcinoid, chromosome 13q, retinoblastoma protein, 39
- Conventional renal cell carcinoma, ionizing radiation, Chernobyl accident, Bcl-2, Bcl-x, BAX, TRAIL-R2 (DR5), NF- κ B (p65, p50), 107
- Curcumin, cell cycle arrest, Cdc25c, cyclin B1, CDK1, Wee1, 55
- Cyclin B1, curcumin, cell cycle arrest, Cdc25c, CDK1, Wee1, 55
- Cyclin kinase inhibitor p21, apoptosis, DNA damage, γ -irradiation, site-directed mutant, 29
- Cytochrome P450, vitamin E, gene expression, rat, liver, HepG2, 183
- Cytokines, GVHD, lymphocytes, quantitative RT-PCR, 113
- Cytoskeletal dynamics, angiogenesis, cancer invasion, cell cycle regulation, growth factor signalling, lymphangiogenesis, metastasis, S100A4, therapeutic target, VEGF signalling, review, 203
- 2-DE databases, MCF7 cell line, proteome, breast cancer, mass spectrometry, 355
- 2-DE protein database, osteosarcoma, Saos2, proteomics, mass spectrometry, MALDI-MS, 325
- Diabetes, proteomics, mass spectrometry, bioinformatics, cancer biology, heart disease, review, 11
- DNA copy number changes, array CGH, uterine leiomyosarcoma, pathway analysis, 347
- DNA damage, cyclin kinase inhibitor p21, apoptosis, γ -irradiation, site-directed mutant, 29
- DNA damage, ovarian cancer, chemotherapy, resistance, 289
- DNA methyltransferases, hepatocellular carcinoma, promoter hypermethylation, tumor suppressor genes, 271
- DNA microarray technology, hepatocellular carcinoma, hepatitis B, hepatitis C, review, 311
- DNA microarray, osteosarcoma, cisplatin, drug-resistance, 373
- DNA microarray, prognosis prediction, gene expression profile, CD133, acute myeloid leukemia, 169
- DNA ploidy, lung adenocarcinoma, comparative genomic hybridization, laser scanning cytometry, prognosis, lymph node metastasis, 265
- Drug delivery, cancer chemotherapy, nanoparticles, polymer- and liposome-systems, magnetic nanohybrids, review, 147
- Drug resistance, neoadjuvant fluorouracil, epirubicin and cyclophosphamide chemotherapy, breast cancer, gene expression profiles, 89
- Drug-resistance, osteosarcoma, cisplatin, DNA microarray, 373
- Egr-1, fibrosarcoma, angiogenesis, invasion, metastasis, protein arrays, TIMP-2, 71
- Electrochemical array (ECA) chip, ferrocenyl-naphthalene-diimide (FND), *k-ras* mutation, restriction enzyme BstNI, asymmetric PCR (A-PCR), 47
- Electron transport chain, oxidative stress, mitochondria, coenzyme Q10, lipid peroxidation, chemotherapy, antioxidants, lipid replacement, 159
- Ensemble learning, gene expression, classification, support vector machines, boosting, feature selection, 63
- Epirubicin and cyclophosphamide chemotherapy, neoadjuvant fluorouracil, breast cancer, gene expression profiles, drug resistance, 89
- Euprostheno*s, spidroin 1 gene, mammalian cells, spider silk protein, 83
- Feature selection, gene expression, classification, support vector machines, boosting, ensemble learning, 63
- Ferrocenyl-naphthalene-diimide (FND), electrochemical array (ECA) chip, *k-ras* mutation, restriction enzyme BstNI, asymmetric PCR (A-PCR), 47
- Fibrosarcoma, Egr-1, angiogenesis, invasion, metastasis, protein arrays, TIMP-2, 71
- Field effect, imaging mass spectrometry, tumor microenvironment, 279
- Galectin-3, thyroid diseases, proteomics, immunodetection, papillary carcinoma, 389
- Gamma radiation, transcriptome, low doses, stress kinases, ceramide, 295
- Gene expression profile, DNA microarray, prognosis prediction, CD133, acute myeloid leukemia, 169
- Gene expression profiles, neoadjuvant fluorouracil, epirubicin and cyclophosphamide chemotherapy, breast cancer, drug resistance, 89
- Gene expression, classification, support vector machines, boosting, ensemble learning, feature selection, 63
- Gene expression, KGFR, cDNA cancer array, cancer, progression, 369
- Gene expression, pancreatic cancer, proteomic, profiling, review, 1
- Gene expression, vitamin E, cytochrome P450, rat, liver, HepG2, 183
- Genomic instability, breast cancer, chromosomal abnormalities, cancer progression, review, 137
- Genomics, nucleic acids, photoablation, IR, LCM, LMD, LPC, proteomics, UV, review, 217
- Growth factor signalling, angiogenesis, cancer invasion, cell cycle regulation, cytoskeletal dynamics, lymphangiogenesis, metastasis, S100A4, therapeutic target, VEGF signalling, review, 203
- GVHD, cytokines, lymphocytes, quantitative RT-PCR, 113
- Heart disease, proteomics, mass spectrometry, bioinformatics, cancer biology, diabetes, review, 11
- Hepatitis B, DNA microarray technology, hepatocellular carcinoma, hepatitis C, review, 311
- Hepatitis C, DNA microarray technology, hepatocellular carcinoma, hepatitis B, review, 311
- Hepatocellular carcinoma, CDP-diacylglycerol synthase 1, methylation, mutation analysis, 231
- Hepatocellular carcinoma, DNA microarray technology, hepatitis B, hepatitis C, review, 311
- Hepatocellular carcinoma, promoter hypermethylation, DNA methyltransferases, tumor suppressor genes, 271
- HepG2, vitamin E, cytochrome P450, gene expression, rat, liver, 183
- Human herpesvirus 8, classic Kaposi's sarcoma, human leukocyte antigens, 191
- Human leukocyte antigens, classic Kaposi's sarcoma, human herpesvirus 8, 191
- Imaging mass spectrometry, tumor microenvironment, field effect, 279
- Immunodetection, galectin-3, thyroid diseases, proteomics, papillary carcinoma, 389

- Invasion front, renal cell cancer, p27^{Kip1} protein, prognosis, 239
- Invasion, Egr-1, fibrosarcoma, angiogenesis, metastasis, protein arrays, TIMP-2, 71
- Ionizing radiation, conventional renal cell carcinoma, Chernobyl accident, Bcl-2, Bcl-x, BAX, TRAIL-R2 (DR5), NF-κB (p65, p50), 107
- IR, nucleic acids, photoablation, LCM, LMD, LPC, genomics, proteomics, UV, review, 217
- γ-Irradiation, cyclin kinase inhibitor p21, apoptosis, DNA damage, site-directed mutant, 29
- K-ras* mutation, electrochemical array (ECA) chip, ferrocenyl-naphthalene-diimide (FND), restriction enzyme BstNI, asymmetric PCR (A-PCR), 47
- KGFR, cDNA cancer array, cancer, gene expression, progression, 369
- Laser scanning cytometry, lung adenocarcinoma, comparative genomic hybridization, DNA ploidy, prognosis, lymph node metastasis, 265
- LCM, nucleic acids, photoablation, IR, LMD, LPC, genomics, proteomics, UV, review, 217
- Lipid peroxidation, oxidative stress, mitochondria, coenzyme Q10, electron transport chain, chemotherapy, antioxidants, lipid replacement, 159
- Lipid replacement, oxidative stress, mitochondria, coenzyme Q10, lipid peroxidation, electron transport chain, chemotherapy, antioxidants, 159
- Liver proteins, small heterodimer partner, transgenic mice, proteomics, 119
- Liver, vitamin E, cytochrome P450, gene expression, rat, HepG2, 183
- LMD, nucleic acids, photoablation, IR, LCM, LPC, genomics, proteomics, UV, review, 217
- Low doses, transcriptome, gamma radiation, stress kinases, ceramide, 295
- LPC, nucleic acids, photoablation, IR, LCM, LMD, genomics, proteomics, UV, review, 217
- Lung adenocarcinoma, comparative genomic hybridization, laser scanning cytometry, DNA ploidy, prognosis, lymph node metastasis, 265
- Lung cancer, microarrays, review, 197
- Lung, carcinoid, chromosome 13q, comparative genomic hybridization, retinoblastoma protein, 39
- Lymph node metastasis, lung adenocarcinoma, comparative genomic hybridization, laser scanning cytometry, DNA ploidy, prognosis, 265
- Lymphangiogenesis, angiogenesis, cancer invasion, cell cycle regulation, cytoskeletal dynamics, growth factor signalling, metastasis, S100A4, therapeutic target, VEGF signalling, review, 203
- Lymphocytes, GVHD, cytokines, quantitative RT-PCR, 113
- Magnetic nano hybrids, drug delivery, cancer chemotherapy, nanoparticles, polymer- and liposome-systems, review, 147
- MALDI-MS, osteosarcoma, Saos2, proteomics, 2-DE protein database, mass spectrometry, 325
- Mammalian cells, spidroin 1 gene, Euprosthenops, spider silk protein, 83
- Mass spectrometry, MCF7 cell line, proteome, breast cancer, 2-DE databases, 355
- Mass spectrometry, osteosarcoma, Saos2, proteomics, 2-DE protein database, MALDI-MS, 325
- Mass spectrometry, proteomics, bioinformatics, cancer biology, heart disease, diabetes, review, 11
- MCF7 cell line, proteome, breast cancer, mass spectrometry, 2-DE databases, 355
- Metastasis, angiogenesis, cancer invasion, cell cycle regulation, cytoskeletal dynamics, growth factor signalling, lymphangiogenesis, S100A4, therapeutic target, VEGF signalling, review, 203
- Metastasis, Egr-1, fibrosarcoma, angiogenesis, invasion, protein arrays, TIMP-2, 71
- Methylation, CDP-diacylglycerol synthase 1, hepatocellular carcinoma, mutation analysis, 231
- Microarray, ABC transporter, cluster analysis, multidrug resistance, 97
- Microarray, neuroblastoma, CGH, MYCN, chromosome 1p, 245
- Microarray, resveratrol, PI3K pathway, c-fos, p70S6K, cancer prevention, predictive cancer markers, 383
- Microarrays, lung cancer, review, 197
- MicroRNA, RNA interference, siRNA, cancer, review, 127
- MiRNA, colon cancer, S-1, 317
- Mitochondria, oxidative stress, coenzyme Q10, lipid peroxidation, electron transport chain, chemotherapy, antioxidants, lipid replacement, 159
- Multidrug resistance, ABC transporter, cluster analysis, microarray, 97
- Mutation analysis, CDP-diacylglycerol synthase 1, hepatocellular carcinoma, methylation, 231
- MYCN, neuroblastoma, microarray, CGH, chromosome 1p, 245
- Nanoparticles, drug delivery, cancer chemotherapy, polymer- and liposome-systems, magnetic nano hybrids, review, 147
- Neoadjuvant fluorouracil, epirubicin and cyclophosphamide chemotherapy, breast cancer, gene expression profiles, drug resistance, 89
- Neuroblastoma, microarray, CGH, MYCN, chromosome 1p, 245
- NF-κB (p65, conventional renal cell carcinoma, ionizing radiation, Chernobyl accident, Bcl-2, Bcl-x, BAX, TRAIL-R2 (DR5), p50), 107
- Nucleic acids, photoablation, IR, LCM, LMD, LPC, genomics, proteomics, UV, review, 217
- Osteosarcoma, cisplatin, drug-resistance, DNA microarray, 373
- Osteosarcoma, Saos2, proteomics, 2-DE protein database, mass spectrometry, MALDI-MS, 325
- Ovarian cancer, chemotherapy, resistance, DNA damage, 289
- Oxidative stress, mitochondria, coenzyme Q10, lipid peroxidation, electron transport chain, chemotherapy, antioxidants, lipid replacement, 159
- P27Kip1 protein, renal cell cancer, prognosis, invasion front, 239
- P70S6K, resveratrol, PI3K pathway, c-fos, cancer prevention, predictive cancer markers, microarray, 383
- Pancreatic cancer, gene expression, proteomic, profiling, review, 1
- Papillary carcinoma, galectin-3, thyroid diseases, proteomics, immunodetection, 389
- Pathway analysis, array CGH, DNA copy number changes, uterine leiomyosarcoma, 347

- Photoablation, nucleic acids, IR, LCM, LMD, LPC, genomics, proteomics, UV, review, 217
- PI3K pathway, resveratrol, c-fos, p70S6K, cancer prevention, predictive cancer markers, microarray, 383
- Polymer- and liposome-systems, drug delivery, cancer chemotherapy, nanoparticles, magnetic nanohybrids, review, 147
- Predictive cancer markers, resveratrol, PI3K pathway, c-fos, p70S6K, cancer prevention, microarray, 383
- Profiling, pancreatic cancer, gene expression, proteomic, review, 1
- Promoter hypermethylation, hepatocellular carcinoma, DNA methyltransferases, tumor suppressor genes, 271
- Protein arrays, Egr-1, fibrosarcoma, angiogenesis, invasion, metastasis, TIMP-2, 71
- Proteome, MCF7 cell line, breast cancer, mass spectrometry, 2-DE databases, 355
- Proteomic, pancreatic cancer, gene expression, profiling, review, 1
- Proteomics, biomarkers, blood plasma, serum, review, 227
- Proteomics, cancer diagnosis, biomarkers, review, 253
- Proteomics, galectin-3, thyroid diseases, immunodetection, papillary carcinoma, 389
- Proteomics, mass spectrometry, bioinformatics, cancer biology, heart disease, diabetes, review, 11
- Proteomics, nucleic acids, photoablation, IR, LCM, LMD, LPC, genomics, UV, review, 217
- Proteomics, osteosarcoma, Saos2, 2-DE protein database, mass spectrometry, MALDI-MS, 325
- Proteomics, small heterodimer partner, transgenic mice, liver proteins, 119
- Quantitative RT-PCR, GVHD, cytokines, lymphocytes, 113
- Rat, vitamin E, cytochrome P450, gene expression, liver, HepG2, 183
- Renal cell cancer, p27^{Kip1} protein, prognosis, invasion front, 239
- Resistance, ovarian cancer, chemotherapy, DNA damage, 289
- Restriction enzyme BstNI, electrochemical array (ECA) chip, ferrocenyl-naphthalene-diimide (FND), *k-ras* mutation, asymmetric PCR (A-PCR), 47
- Resveratrol, PI3K pathway, c-fos, p70S6K, cancer prevention, predictive cancer markers, microarray, 383
- Retinoblastoma protein, lung, carcinoid, chromosome 13q, comparative genomic hybridization, 39
- Review, angiogenesis, cancer invasion, cell cycle regulation, cytoskeletal dynamics, growth factor signalling, lymphangiogenesis, metastasis, S100A4, therapeutic target, VEGF signalling, 203
- Review, DNA microarray technology, hepatocellular carcinoma, hepatitis B, hepatitis C, 311
- Review, drug delivery, cancer chemotherapy, nanoparticles, polymer- and liposome-systems, magnetic nanohybrids, 147
- Review, genomic instability, breast cancer, chromosomal abnormalities, cancer progression, 137
- Review, microarrays, lung cancer, 197
- Review, nucleic acids, photoablation, IR, LCM, LMD, LPC, genomics, proteomics, UV, 217
- Review, pancreatic cancer, gene expression, proteomic, profiling, 1
- Review, proteomics, biomarkers, blood plasma, serum, 227
- Review, proteomics, cancer diagnosis, biomarkers, 253
- Review, proteomics, mass spectrometry, bioinformatics, cancer biology, heart disease, diabetes, 11
- Review, RNA interference, siRNA, microRNA, cancer, 127
- RNA interference, siRNA, microRNA, cancer, review, 127
- S-1, miRNA, colon cancer, 317
- S100A4, angiogenesis, cancer invasion, cell cycle regulation, cytoskeletal dynamics, growth factor signalling, lymphangiogenesis, metastasis, therapeutic target, VEGF signalling, review, 203
- Saos2, osteosarcoma, proteomics, 2-DE protein database, mass spectrometry, MALDI-MS, 325
- Serum, proteomics, biomarkers, blood plasma, review, 227
- SiRNA, RNA interference, microRNA, cancer, review, 127
- Site-directed mutant, cyclin kinase inhibitor p21, apoptosis, DNA damage, γ -irradiation, 29
- Small heterodimer partner, transgenic mice, liver proteins, proteomics, 119
- Spider silk protein, spidroin 1 gene, Euprosthens, mammalian cells, 83
- Spidroin 1 gene, Euprosthens, mammalian cells, spider silk protein, 83
- Stress kinases, transcriptome, gamma radiation, low doses, ceramide, 295
- Support vector machines, gene expression, classification, boosting, ensemble learning, feature selection, 63
- Thyroid diseases, galectin-3, proteomics, immunodetection, papillary carcinoma, 389
- TIMP-2, Egr-1, fibrosarcoma, angiogenesis, invasion, metastasis, protein arrays, 71
- TRAIL-R2 (DR5), conventional renal cell carcinoma, ionizing radiation, Chernobyl accident, Bcl-2, Bcl-x, BAX, NF- κ B (p65, p50), 107
- Transcriptome, gamma radiation, low doses, stress kinases, ceramide, 295
- Transgenic mice, small heterodimer partner, liver proteins, proteomics, 119
- Tumor microenvironment, imaging mass spectrometry, field effect, 279
- Tumor suppressor genes, hepatocellular carcinoma, promoter hypermethylation, DNA methyltransferases, 271
- Uterine leiomyosarcoma, array CGH, DNA copy number changes, pathway analysis, 347
- UV, nucleic acids, photoablation, IR, LCM, LMD, LPC, genomics, proteomics, review, 217
- VEGF signalling, angiogenesis, cancer invasion, cell cycle regulation, cytoskeletal dynamics, growth factor signalling, lymphangiogenesis, metastasis, S100A4, therapeutic target, review, 203
- Vitamin E, cytochrome P450, gene expression, rat, liver, HepG2, 183
- Wee1, curcumin, cell cycle arrest, Cdc25c, cyclin B1, CDK1, 55

Authors Index

(Figures refer to page numbers)

- Agliardi C, 191
 Ahmed FE, 217
 Akutsu M, 169
 Albino D, 245
 Alkhalaf M, 383
 Amano M, 47
 Anagnostopoulos AK, 325
 Arai D, 29
 Arai Y, 169
 Bahr SJ, 369
 Banoub J, 311
 Barella L, 183
 Bernard-Gallon D, 113
 Bertholet V, 97
 Bezerianos A, 63
 Biffi R, 191
 Bignon YJ, 89, 113
 Böhling T, 347
 Bonassi S, 245
 Boneschi V, 191
 Boulias K, 119
 Brackett DJ, 369
 Brambati M, 191
 Brambilla L, 191
 Bray I, 127
 Breen L, 197
 Brentnall TA, 1
 Bützow R, 347
 Caldwell RL, 279
 Champion L, 89
 Campone M, 89
 Canelle L, 355
 Caprioli RM, 279
 Caron M, 355
 Chalabi N, 113
 Chan A, 271
 Chang JG, 231
 Charbonnel C, 89
 Chen GWI, 55
 Chen L, 71
 Chen R, 1
 Chen YL, 231
 Chevillard S, 295
 Choi YL, 169
 Choufi B, 113
 Chung JG, 55
 Clynes M, 127, 197
 Coco S, 245
 Conklin KA, 159
 Crispin DA, 1
 De Longueville F, 97
 Defferrari R, 245
 Delort L, 113
 Déporte-Féty R, 89
 Deslandes Y, 147
 Dimitraki P, 119
 Dragomir A, 63
 Effertth T, 97
 El-Aneed A, 311
 Engström W, 83
 Fernandez-Arias A, 83
 Ferrante P, 191
 Ferrucci S, 191
 Fountoulakis M, 119
 Frank J, 183
 Fujiwara MI, 39
 Fujiwara SI, 169
 Fukuchi K, 29
 Furuta R, 39
 Garbis S, 119
 Gentile M, 347
 Gerçel-Taylor ², 289
 Gillet JP, 97
 Gomi K, 29
 Gonzalez A, 279
 Gorgoulis VG, 325
 Gouraud W, 89
 Grip S, 83
 Guerini FR, 191
 Hamano K, 265
 Hardouin J, 355
 Hayashi K, 317
 Hayashi M, 265
 Hirai Y, 169
 Hsieh TH, 147
 Huang R, 71
 Huang RP, 71
 Hundhausen C, 183
 Ifandi V, 253
 Inamura K, 39
 Ingvarsson S, 137
 Ishikawa N, 47
 Ishikawa Y, 39
 Jézéquel P, 89
 Jinbo M, 265
 Jonas U, 239
 Joubert-Caron R, 355
 Joyce H, 127
 Ju J, 317
 Jurisica I, 11
 Kanazawa Y, 373
 Kaneda R, 169
 Kaneda Y, 265
 Kano Y, 169
 Kaur S, 347
 Khan M, 253
 Kislinger T, 11
 Kittas C, 325
 Knuutila S, 347
 Kobierski A, 239
 Koivisto-Korander R, 347
 Kouyianou K, 119
 Kuczyk M, 239
 Kudo K, 317
 Lai PBS, 271
 Lam TW, 271
 Lan CQ, 147
 Larramendy ML, 347
 Lasserre JP, 355
 Le Corre L, 113
 Leminen A, 347
 Lerner MR, 369
 Levalois C, 295
 Li S, 71
 Li TS, 265
 Liew CT, 271
 Lin JG, 55
 Lin WC, 55
 Llombart-Bosch A, 107
 Lundblad RL, 227
 Magrangeas F, 89
 Malfoy B, 295
 Mancuso R, 191
 Mano H, 169
 Maximilien R, 295
 Mazzocco K, 245
 McQueen-Mason SJ, 83
 Mengel M, 239
 Merseburger AS, 239
 Millour M, 89
 Minvielle S, 89
 Mitani K, 169
 Miya T, 47
 Miyazaki Y, 169
 Mizumoto K, 47
 Morell-Quadreny L, 107
 Moretti S, 245
 Muller PY, 183
 Nagai E, 47
 Nakagawa K, 39
 Nakajima G, 317
 Nicolson CL, 159
 Niforou KN, 325
 Nimmervoll H, 83
 Nomura N, 29
 O' Driscoll L, 197
 O'Neill MC, 169
 Ohashi J, 169
 Ohuchida K, 47
 Okumura S, 39
 Oppenheimer SR, 279
 Ory K, 295
 Ozawa K, 169
 Pan S, 1
 Penault-Llorca F, 89
 Pento JT, 369
 Post M, 147
 Pouchkina-Stantcheva N, 83
 Punyarit P, 389
 Rachid O, 383
 Ramos D, 107
 Randall-Whitis L, 289
 Remacle J, 97
 Rigaud O, 295
 Rimbach G, 183
 Rising A, 83
 Romanenko A, 107
 Sadao I, 373
 Sapan CV, 227
 Satih S, 113
 Satoh Y, 39
 Scaruffi P, 245
 Schneider J, 97
 Schwartz HS, 279
 Serth J, 239
 Sheinin I, 347
 Sherbet GV, 203
 Shirakawa T, 39
 Simard B, 147
 Slade SE, 253
 Srisomsap C, 389
 Stoecklin E, 183
 Storckenfeldt E, 83
 Su CC, 55
 Su WW, 231
 Subhasitanont P, 389
 Svarvar C, 347
 Svasti J, 389
 Takasaki K, 317
 Takazawa K, 373
 Takenaka S, 47
 Tanaka M, 47
 Tang KP, 231
 Taylor DD, 289
 Teramura M, 169
 To KF, 271
 Tomita K, 373
 Tomonaga M, 169
 Tong JHM, 271
 Tonini GP, 245
 Tsangaris GT, 325
 Tsiotis G, 119
 Tsuchiya E, 39
 Tsuchiya H, 373
 Tsutsumi C, 169
 Uchida K, 317

Ueda K, 265
Ugolin N, 295
Urabe A, 169
Usuki K, 169
Vauhkonen H, 347
Vlieghe C, 355
Vollrath F, 83

Von Der Heyde E, 239
Vougas K, 325
Vozianov A, 107
Wang YF, 231
Wegener U, 239
Wong N, 271
Xi Y, 317

Yamaguchi K, 47
Yamamoto M, 317
Yamashita Y, 169
Yang W, 71
Yao C, 71
Yeh KT, 231
Yoshimichi U, 373

Zanetta L, 191
Zang XP, 369
Zanzottera M, 191
Zhang J, 147

Instructions to Authors

General Policy. CANCER GENOMICS & PROTEOMICS (CGP) welcomes the submission of high quality original articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board.

A main aim of CGP is to ensure for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to CGP will be subject to review by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to CGP are treated in confidence, with access restricted to the Editor-in-Chief, the Managing Editor, the journal's secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts in terms of grammar and style.

Copyright. On publication of a manuscript in CGP, which is a copyrighted publication, the legal ownership of all published parts of the paper passes from the Author(s) to the Journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor.

Format. Two types of papers may be submitted: (i) full papers containing completed original work, and (ii) review articles concerning fields of recognizable progress. Papers should contain all the essential data in order to make the presentation clear. Papers should be written in clear, concise English. Spelling should follow that of the "Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double-spaced page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four (4) printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 2000 words, organized according to the following headings: Background - Materials and Methods or Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods or Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements and (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's preference. Review articles should not exceed 35 pages (approximately 250 words per double-spaced page) including all tables, figures and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, rather than photographic copies. A charge will be made for a colour plate. Figures should be numbered with Arabic numerals and include a short title, and legend if appropriate.

Tables. Each table should be submitted on a separate page, double-spaced. Tables should be numbered with Roman numerals and should include a short title, and legend if appropriate.

References. Authors must assume responsibility for the accuracy of the references used. Citations for the reference section of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively in the order that they appear in the text. Examples: 1 Summer AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2. McGuire WL and Chamness GC: Studies on the oestrogen receptor in breast cancer. *In: Receptors for Reproductive Hormones* (O' Malley BW and Chamness GC, eds.). New York, Plenum Publ Corp, pp.133-136, 1973. In the text, references should be denoted as: (1), (2-5), (6, 7) etc.

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC-IUB", "Bergey's Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

Ethical Policies and Standards. CGP agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human fetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. An original and two copies of the manuscript (including all photographs and graphs) should be sent to: Dr. J.G. Delinassios, Managing Editor, Cancer Genomics and Proteomics, International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki 19014, Greece. A CD-ROM, floppy disc, or ZIP-disc should also be submitted indicating the computer-processing program. Additionally, for speed of processing, manuscripts may be sent by e-mail to www.cgp-journal.com. Authors are invited to submit, along with their manuscripts, a short list of possible reviewers and any previous publications which could facilitate reviewing. Only the original copy of the submitted manuscript will be returned to the Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent by e-mail to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free of charge. Additional copies may be ordered after acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.

CANCER GENOMICS & PROTEOMICS supports (a) the establishment and the activities of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (Kapandriti, Attiki, Greece) and (b) the organization of the International Conferences of Anticancer Research.

For more information about CANCER GENOMICS & PROTEOMICS, IAR and the Conferences please visit the IAR website: www.iar-anticancer.org

Publication Data: CANCER GENOMICS & PROTEOMICS (CGP) is published bimonthly. Each annual volume contains six issues. Annual Authors and Subject Indexes are included in the sixth issue of each volume.

Copyright: Once a manuscript has been published in CGP, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author to the Journal.

Manuscripts, correspondence, requests for sample copies and orders should be addressed to: Dr John G. Delinassios, Managing Editor, Editorial Office, Cancer Genomics & Proteomics, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, Kapandriti, Attiki, 19014, Greece. Tel: 0030 22950 52945, Fax: 0030 22950 53389, e-mail (Editorial Office): journals@iar-anticancer.org, e-mail (Managing Editor): editor@iar-anticancer.org

Manuscripts from North America may be sent to the Editor-in-Chief, Prof. A. Seth, CGP, Laboratory of Molecular Pathology, Sunnybrook and Women's College Health Sciences Center, 2075 Bayview Avenue, Room E-423, Toronto, ON, Canada M4N 3M5. Fax: 416 978 5956, e-mail: genomics.proteomics@utoronto.ca

Annual Subscription (print and online) Rates 2004, 2005, 2006, 2007: Institutional subscription: Euro 800 per volume. Personal subscription: Euro 400 per volume. Prices include rapid delivery and insurance.

Subscription Orders: Orders can be placed at agencies, bookstores, or directly with the publisher. Cheques should be made payable to J.G. Delinassios, Managing Editor, Athens, Greece and should be sent to the Editorial Office.

Advertising: Correspondence and rate requests should be addressed to the Editorial Office.

Book Reviews: Recently published books and journals should be sent to the Editorial Office. Reviews will be published within 2-4 months.

The Editors and Publishers of the journal CANCER GENOMICS & PROTEOMICS accept no responsibility for the opinions expressed by the contributors or for the content of the advertisements appearing therein.